<efrbr:recordSet xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:efrbr="http://vfrbr.info/efrbr/1.1" xmlns:efrbr-work="http://vfrbr.info/efrbr/1.1/work" xmlns:efrbr-expression="http://vfrbr.info/efrbr/1.1/expression" xmlns:efrbr-manifestation="http://vfrbr.info/efrbr/1.1/manifestation" xmlns:efrbr-person="http://vfrbr.info/efrbr/1.1/person" xmlns:efrbr-corporateBody="http://vfrbr.info/efrbr/1.1/corporateBody" xmlns:efrbr-concept="http://vfrbr.info/efrbr/1.1/concept" xmlns:efrbr-structure="http://vfrbr.info/efrbr/1.1/structure" xmlns:efrbr-responsible="http://vfrbr.info/efrbr/1.1/responsible" xmlns:efrbr-subject="http://vfrbr.info/efrbr/1.1/subject" xmlns:efrbr-other="http://vfrbr.info/efrbr/1.1/other" xsi:schemaLocation="http://vfrbr.info/efrbr/1.1 http://vfrbr.info/schemas/1.1/efrbr.xsd"><efrbr:entities><efrbr-work:work identifier="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789"><efrbr-work:titleOfTheWork>Identification of novel chromone based sulfonamides as highly potent and selective inhibitors of alkaline phosphatases</efrbr-work:titleOfTheWork></efrbr-work:work><efrbr-expression:expression identifier="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789"><efrbr-expression:titleOfTheExpression>Identification of novel chromone based sulfonamides as highly potent and selective inhibitors of alkaline phosphatases</efrbr-expression:titleOfTheExpression><efrbr-expression:formOfExpression vocabulary="DIAS:TYPES">
            Peer-Reviewed Journal Publication
            Δημοσίευση σε Περιοδικό με Κριτές
         </efrbr-expression:formOfExpression><efrbr-expression:dateOfExpression type="issued">2015-12-03</efrbr-expression:dateOfExpression><efrbr-expression:dateOfExpression type="published">2013</efrbr-expression:dateOfExpression><efrbr-expression:languageOfExpression vocabulary="iso639-1">en</efrbr-expression:languageOfExpression><efrbr-expression:summarizationOfContent>A new series of structurally diverse chromone containing sulfonamides has been developed. Crystal structures of three representative compounds (2a, 3a and 4a) in the series are reported. All compounds were screened for their inhibitory potential against alkaline phosphatases (ALPs). Two main classes of ALP isozymes were selected for this study, the tissue non-specific alkaline phosphatase (TNALP) from bovine and porcine source and the tissue-specific intestinal alkaline phosphatases (IALPs) from bovine source. All sulfonamide compounds had a marked preference for IALP (Ki, up to 0.01 ± 0.001 μM) over TNALPs. Kinetics studies of the compounds showed competitive mode of inhibition. Molecular docking studies were carried out in order to characterize the selective inhibition of the compounds. An additional interesting aspect of these chromone sulfonamides is their inhibitory activity against ecto-5′-nucleotidase enzyme.</efrbr-expression:summarizationOfContent><efrbr-expression:useRestrictionsOnTheExpression type="creative-commons">http://creativecommons.org/licenses/by/4.0/</efrbr-expression:useRestrictionsOnTheExpression><efrbr-expression:note type="journal name">European Journal of Medicinal Chemistry</efrbr-expression:note><efrbr-expression:note type="journal volume">66</efrbr-expression:note><efrbr-expression:note type="page range">438-449</efrbr-expression:note></efrbr-expression:expression><efrbr-person:person identifier="331D28A9-E508-495C-863D-57669B3AC6D8"><efrbr-person:nameOfPerson vocabulary="">
            Mariya al-Rashida
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="CD40C859-0FF1-4991-A20A-0388A419E566"><efrbr-person:nameOfPerson vocabulary="">
            Rabia Raza
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="0485646B-0E14-4F17-9DA3-7C9E6D5E962F"><efrbr-person:nameOfPerson vocabulary="">
            Ghulam Abbas
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="5793D247-C224-43A3-AF20-91F756C8288A"><efrbr-person:nameOfPerson vocabulary="">
            Muhammad Shakil Shah
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="http://users.isc.tuc.gr/~gkostakis"><efrbr-person:nameOfPerson vocabulary="TUC:LDAP">
            Kostakis Georgios
            Κωστακης Γεωργιος
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="BB645085-D850-47E1-BE26-7EF5297A3D4F"><efrbr-person:nameOfPerson vocabulary="">
             Joanna Lecka
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="72D0E6C5-1327-4D15-8D18-4A04F531A6D4"><efrbr-person:nameOfPerson vocabulary="">
            Jean Sévigny
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="E94C3CF2-ECEC-4688-8BE3-573C44F3242D"><efrbr-person:nameOfPerson vocabulary="">
            Muhammad Muddassar
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="A7639D8C-A1B6-4D70-9B96-32E20A03E547"><efrbr-person:nameOfPerson vocabulary="">
            Constantina Papatriantafyllopoulou
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="0D1A310A-A7FC-45A2-B2CF-31C89AB144EA"><efrbr-person:nameOfPerson vocabulary="">
             Jamshed Iqbal
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-corporateBody:corporateBody identifier="http://www.cell.com/cellpress"><efrbr-corporateBody:nameOfTheCorporateBody vocabulary="S/R:PUBLISHERS">
            Elsevier
         </efrbr-corporateBody:nameOfTheCorporateBody></efrbr-corporateBody:corporateBody><efrbr-concept:concept identifier="55835F0A-24B8-46A4-9978-BE046632A748"><efrbr-concept:termForTheConcept>
            Alkaline phosphatase inhibitors
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="0B893187-9A62-46B1-968A-F0D40EDDDBC7"><efrbr-concept:termForTheConcept>
            Ecto-5′-nucleotidase inhibitors
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="674FF4EB-D377-4425-90C6-D1F47A94E544"><efrbr-concept:termForTheConcept>
            Chromones
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="C15D7070-2600-46E3-9F15-240E1DD7BB81"><efrbr-concept:termForTheConcept>
            Sulfonamides
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="94371E93-8228-462B-8FDB-E4B572A22846"><efrbr-concept:termForTheConcept>
            Molecular docking
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="0C4586E8-9D31-4BC5-994D-39FD95E131D9"><efrbr-concept:termForTheConcept>
            Structure activity relationships (SARs)
         </efrbr-concept:termForTheConcept></efrbr-concept:concept></efrbr:entities><efrbr:relationships><efrbr-structure:structureRelations><efrbr-structure:realizedThrough sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="expression" targetURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789"/></efrbr-structure:structureRelations><efrbr-responsible:responsibleRelations><efrbr-responsible:createdBy sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="331D28A9-E508-495C-863D-57669B3AC6D8"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="331D28A9-E508-495C-863D-57669B3AC6D8" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="CD40C859-0FF1-4991-A20A-0388A419E566" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="0485646B-0E14-4F17-9DA3-7C9E6D5E962F" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="5793D247-C224-43A3-AF20-91F756C8288A" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="http://users.isc.tuc.gr/~gkostakis" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="BB645085-D850-47E1-BE26-7EF5297A3D4F" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="72D0E6C5-1327-4D15-8D18-4A04F531A6D4" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="E94C3CF2-ECEC-4688-8BE3-573C44F3242D" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="A7639D8C-A1B6-4D70-9B96-32E20A03E547" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="0D1A310A-A7FC-45A2-B2CF-31C89AB144EA" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="person" targetURI="http://www.cell.com/cellpress" role="publisher"/></efrbr-responsible:responsibleRelations><efrbr-subject:subjectRelations><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="concept" targetURI="55835F0A-24B8-46A4-9978-BE046632A748"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="concept" targetURI="0B893187-9A62-46B1-968A-F0D40EDDDBC7"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="concept" targetURI="674FF4EB-D377-4425-90C6-D1F47A94E544"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="concept" targetURI="C15D7070-2600-46E3-9F15-240E1DD7BB81"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="concept" targetURI="94371E93-8228-462B-8FDB-E4B572A22846"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/BB4F4358-458D-48EF-86FE-104612E2E789" targetEntity="concept" targetURI="0C4586E8-9D31-4BC5-994D-39FD95E131D9"/></efrbr-subject:subjectRelations><efrbr-other:otherRelations/></efrbr:relationships></efrbr:recordSet>